160 related articles for article (PubMed ID: 11698565)
21. Risk-benefit profiles of women using tamoxifen for chemoprevention.
Nichols HB; DeRoo LA; Scharf DR; Sandler DP
J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
[TBL] [Abstract][Full Text] [Related]
22. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
23. Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment.
Veronesi A; Pizzichetta MA; Ferlante MA; Zottar M; Magri MD; Crivellari D; Foladore S
Tumori; 1998; 84(3):372-5. PubMed ID: 9678620
[TBL] [Abstract][Full Text] [Related]
24. Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project.
Day R;
Ann N Y Acad Sci; 2001 Dec; 949():143-50. PubMed ID: 11795346
[TBL] [Abstract][Full Text] [Related]
25. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
26. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
Fisher B; Costantino JP; Redmond CK; Fisher ER; Wickerham DL; Cronin WM
J Natl Cancer Inst; 1994 Apr; 86(7):527-37. PubMed ID: 8133536
[TBL] [Abstract][Full Text] [Related]
27. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.
Iqbal J; Ginsburg OM; Wijeratne TD; Howell A; Evans G; Sestak I; Narod SA
Cancer Treat Rev; 2012 Jun; 38(4):318-28. PubMed ID: 21775065
[TBL] [Abstract][Full Text] [Related]
28. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
30. Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).
Smith SG; Sestak I; Howell A; Forbes J; Cuzick J
J Clin Oncol; 2017 Aug; 35(23):2666-2673. PubMed ID: 28661758
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
32. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
Tormey DC; Gray R; Falkson HC
J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
[TBL] [Abstract][Full Text] [Related]
34. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Ohsumi S; Shimozuma K; Ohashi Y; Shinji M; Hozumi Y; Mukai H; Takatsuka Y; Aihara T
Breast Cancer Res Treat; 2011 May; 127(1):143-52. PubMed ID: 21347648
[TBL] [Abstract][Full Text] [Related]
36. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.
Radmacher MD; Simon R
J Natl Cancer Inst; 2000 Jan; 92(1):48-53. PubMed ID: 10620633
[TBL] [Abstract][Full Text] [Related]
37. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.
Powles T; Eeles R; Ashley S; Easton D; Chang J; Dowsett M; Tidy A; Viggers J; Davey J
Lancet; 1998 Jul; 352(9122):98-101. PubMed ID: 9672274
[TBL] [Abstract][Full Text] [Related]
38. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
[TBL] [Abstract][Full Text] [Related]
39. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.
Veronesi U; Maisonneuve P; Costa A; Sacchini V; Maltoni C; Robertson C; Rotmensz N; Boyle P
Lancet; 1998 Jul; 352(9122):93-7. PubMed ID: 9672273
[TBL] [Abstract][Full Text] [Related]
40. National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial.
Giles K; Flynn PJ; Dalton R; Zera R
Minn Med; 1993 Dec; 76(12):25-7. PubMed ID: 8127293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]